Guiding Sole Intraoperative Radiotherapy in Breast Cancer According to ASTRO Guidelines: Mitigating Adverse Outcomes in a Taiwan Single‐Center
Cancer Medicine · 2025
DOI: 10.1002/cam4.70537 ↗Kurz gefasst
Leitlinie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Hsin-Yi Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Data Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan. Hauptthemen laut MEDLINE: Breast Neoplasms, Intraoperative Care, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Intraoperative radiotherapy (IORT) is considered a de‐escalating adjuvant treatment for breast cancer low‐risk patients. However, the broader criteria applied by the Taiwan IORT Study Cooperative Group led to an increased rate of locoregional recurrence (LRR) among patients receiving only IORT. Consequently, we revised the criteria for sole IORT treatment to include patients who meet the American Society for Radiation Oncology (ASTRO) eligibility standards. This study aims to investigate how aligning treatment strategies with ASTRO guidelines impacts oncological outcomes in patients receiving IORT.
Methods
From September 2014 to March 2022, a retrospective review of 632 patients with invasive breast cancer undergoing breast‐conserving surgery assessed outcomes following External Beam Radiation Therapy (EBRT), sole IORT, or IORT combined with supplemental EBRT (IORT+boost), with a mean follow‐up period of 4.71 ± 2.10 years. Strategic modifications following the ASTRO guidelines were implemented in April 2021 for sole IORT recipients.
Results
ASTRO‐suitable patients had significantly lower rates of LRR (0.00% vs. 10.64%), distant metastasis (0.00% vs. 4.00%), and any recurrence (0.00% vs. 7.79%) than non‐suitable patients ( p < 0.05). After adjusting for confounders, the overall and non‐suitable patients in the IORT group both exhibited significantly higher hazard ratios for LRR than those in the EBRT group, with values of 5.79 (95% confidence intervals (CI) = 1.75–19.18) and 5.48 (95% CI = 1.66–18.02), respectively.
Conclusions
Aligning treatment criteria with ASTRO guidelines for sole IORT significantly reduces locoregional recurrence rates in patients with invasive breast cancer, highlighting the efficacy of these strategic modifications in improving oncological outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Data Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan.
- Department of Radiation Oncology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan.
- Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan City, Taiwan.
- Department of Surgery, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan.
ORCID-Profile: Yu-Chen Hsu
Zitieren
APA
Yang, H. Y., Tsang, Y. W., Tu, C. W., & Hsu, Y. C. (2025). Guiding Sole Intraoperative Radiotherapy in Breast Cancer According to ASTRO Guidelines: Mitigating Adverse Outcomes in a Taiwan Single‐Center. Cancer Medicine. https://doi.org/10.1002/cam4.70537
Vancouver
Yang HY, Tsang YW, Tu CW, Hsu YC. Guiding Sole Intraoperative Radiotherapy in Breast Cancer According to ASTRO Guidelines: Mitigating Adverse Outcomes in a Taiwan Single‐Center. Cancer Medicine. 2025. doi:10.1002/cam4.70537
BibTeX
@article{Yang2025,
author = {Yang, Hsin-Yi and Tsang, Yuk-Wah and Tu, Chi-Wen and Hsu, Yu-Chen},
title = {Guiding Sole Intraoperative Radiotherapy in Breast Cancer According to ASTRO Guidelines: Mitigating Adverse Outcomes in a Taiwan Single‐Center},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70537}
}
EUVIMED